Marksans Pharma receives USFDA approval for Paricalcitol Capsules

18 Oct 2016 Evaluate

Marksans Pharma has received approval by US Food and Drug Administration (USFDA) for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are therapeutically equivalent to listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc. Paricalcitol is a Synthetic Vitamin D analog. Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism (overactive para thyroid gland). It has been used to reduce parathyroid hormone level.

Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

Marksans Pharma Share Price

178.90 -3.15 (-1.73%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×